Advances in the Use of Recombinant Gonadotropins for Reproductive Biotechnologies in Ruminants: A Review Authors: Vitória Leite Di Domenico, Fabiane Pereira de Moraes, Natália Ávila de Castro, Fernando Caetano de Oliveira, Diogo Magnabosco, Bernardo Garziera Gasperin Published: 2026 ABSTRACT ABSTRACTRecombinant gonadotropins, particularly recombinant follicle‐stimulating hormone (rFSH) and recombinant equine chorionic gonadotropin (reCG), have emerged as viable alternatives to traditional animal‐derived hormones in reproductive biotechnologies. This review aims to provide an updated and comprehensive overview of recombinant gonadotropins, with emphasis on the most recent scientific and technological advances in production and their application. This research integrates studies published following the recent commercial introduction of these molecules and incorporates findings generated by our research group. A total of 12 field studies in ruminants met the inclusion criteria, comprising four evaluating rFSH for superovulation and eight assessing reCG across different reproductive applications. Recent studies demonstrate that rFSH achieves similar superovulatory outcomes to conventional protocols, while reCG effectively promotes follicular growth, ovulation, and fertility in cattle and sheep, with results comparable to purified eCG. Beyond reproductive efficacy, recombinant hormones offer advantages such as reduced animal use, consistent product quality, and simplified management. These findings highlight recombinant gonadotropins as promising, ethical, and efficient tools for advancing assisted reproduction in ruminants. Introduction Gonadotropins, including follicle‐stimulating hormone (FSH) and luteinizing hormone (LH), are glycoproteic hormones primarily synthesized and secreted by the anterior pituitary gland in response to gonadotropin‐releasing hormone (GnRH) synthesized and secreted by the hypothalamus (De Koning et al. 1994). FSH stimulates granulosa cells, promoting follicular recruitment and growth (Gifre et al. 2017), whereas LH is involved in final follicular growth and is essential for ovulation of the pre‐ovulatory follicle. In certain species, gonadotropins can also be produced by the placenta, such as equine chorionic gonadotropin (eCG) (Hassanein et al. 2024), a glycoproteic hormone that, in non‐equine species, exhibits follicle‐stimulating and luteinizing activity (Stewart and Allen 1981). Most gonadotropins used for reproductive purposes are obtained from animal‐derived biological sources, requiring extraction and purification (Baruselli et al. 2023; Gifre et al. 2017). However, purified hormones tend to present batch‐to‐batch variation, resulting from the inherent complexity of biological extraction and purification processes, including the presence of contaminating hormones and other proteins (Lösle et al. 2025). Furthermore, the production of eCG raises significant animal welfare concerns, as it relies on repeated blood collections from pregnant mares (reviewed by Baruselli et al. 2023). Recombinant biotechnology has enabled the production of a wide range of proteins, including FSH and eCG, using mammalian and fungal expression systems (Gifre et al. 2017). The advantages of recombinant hormones are greater consistency and reproducibility, no need for extraction and purification from animals, reduced risk of pathogen transmission, and enhanced quality control (Baruselli et al. 2023; Villarraza et al. 2021). Additionally, according to a review by Baruselli et al. (2023), recombinant gonadotropins can be engineered to exhibit prolonged biological activity, enabling single‐dose administration, reducing handling. The use of recombinant hormones in animal reproduction represents a promising alternative to conventional approaches. Therefore, this review aims to provide an updated and comprehensive overview of recombinant gonadotropins, with emphasis on the most recent scientific and technological advances, integrating studies published following the recent commercial introduction of these molecules and incorporating findings generated by our research group. Unlike previous reviews, which primarily focused on conventional gonadotropins or early experimental developments, this article synthesizes recent datasets from in vivo applications across different reproductive biotechnologies. Furthermore, this review discusses data from the use of recombinant and conventional molecules under commercial conditions, thereby highlighting current gaps and identifying directions for future research and application. Recent Advances in Recombinant FSH Development Ovarian hyperstimulation currently relies on the administration of pituitary‐derived FSH, in combination with other hormones, to promote the growth and maturation of multiple follicles and thereby achieve superovulation (Abreu et al. 2024). However, purified FSH (pFSH) is characterized by a short half‐life of approximately 5 h in cows, due to rapid metabolic clearance and distribution to peripheral tissues (Bó and Mapletoft 2020; Laster 1972). Therefore, purified FSH treatment requires multiple daily administrations to sustain effective follicular stimulation. Due to the limitations associated with the use of purified gonadotropins, recent studies have explored biotechnological alternatives to produce recombinant FSH (rFSH). The recombinant human FSH (rhFSH; follitropin alfa) is a gonadotropin of human origin produced in Chinese hamster ovary (CHO) cells (Khodadadi et al. 2022), which is an immortalized cell line. CHO represents the primary mammalian expression system for large‐scale production of recombinant proteins, owing to the ability to perform efficient post‐translational modifications comparable to those of human cells (Li et al. 2022). rhFSH application in ruminant reproduction has been explored in superovulation for in vivo or in vitro embryo production. However, as noted by Mirzaei et al. (2024), the repeated use of a molecule of human origin may trigger an immunogenic response, potentially reducing the efficacy of rhFSH and long‐acting (LA)‐rhFSH. Considering the immunogenicity‐related issues, there has been a demand to produce specific recombinant gonadotropins for veterinary use. Cabeza et al. (2024), using CHO cell culture, developed and characterized a novel single‐chain bovine FSH variant (bscrFSH—bovine ripafollitropin alfa) designed to overcome the limitations of pituitary‐derived porcine FSH, such as LH contamination, the potential to trigger an immune response in cattle, and the short half‐life. To prolong its half‐life, the molecule was engineered to contain additional N‐glycosylation sites to increase its molecular weight. Superovulation trials in cattle in a decreasing four‐dose regimen confirmed the molecule's efficacy, comparable to outcomes achieved with pituitary‐derived pFSH. The search for alternatives to reduce the number of FSH administrations in bovine superovulation protocols has led to the development of long‐acting molecules such as human (LA‐rhFSH; human corifollitropin alfa) and bovine FSH (LA‐rbFSH; bovine ripafollitropin alfa). The long‐acting molecules are engineered to prolong their half‐life through the insertion of a carboxy‐terminal peptide (CTP) containing multiple glycosylation sites (Ben‐Menahem 2018) (Figure 1). Recent studies in cattle suggest that LA‐rhFSH can promote sustained follicular growth and simplify superovulation protocols with only one FSH application, thereby reducing animal handling, labour, and costs (Viana et al. 2024; Mirzaei et al. 2024). However, as rhFSH, its human origin may cause immunogenic reactions that compromise the results of the protocol. Schematic diagram comparing the glycoprotein structures of conventional purified porcine FSH (extracted from porcine pituitary gland) and long‐acting recombinant bovine ripafollitropin alfa. Arrows highlight key recombinant modifications in the long‐acting version, including additional glycosylation sites and C‐terminal peptide (CTP) insertion, which confer extended half‐life and reduced administration frequency. The integrated flowchart depicts the recombinant production process: (1) recombinant DNA construction (with CTP modification), (2) transfection into CHO cells, (3) protein expression and glycosylation, and (4) purification. CHO: Chinese hamster ovary; CTP: C‐terminal peptide; FSH: follicle‐stimulating hormone. Accordingly, due to the demand for molecules of veterinary origin, Villarraza et al. (2024) developed a LA‐rbFSH produced in CHO. The LA‐rbFSH variant exhibited a purity level of 99%, with a more extensive glycosylation profile and higher sialic acid content—characteristics associated with enhanced circulatory stability. Furthermore, LA‐rbFSH demonstrated higher plasma concentrations and a specific in vivo bioactivity 2.4 times greater than bscrFSH. Abreu et al. (2024) investigated an alternative to CHO, the non‐pathogenic unicellular protozoan Leishmania tarentolae as a host to produce bioactive bscrFSH. L. tarentolae can be cultured in vitro at high cell densities and exhibits a glycosylation highly similar to mammalian N‐glycosylation. They produced a biologically active form of bscrFSH, which stimulated follicular growth in a dose‐dependent manner. This study represents an advance in the use of non‐conventional systems for the expression of complex glycoprotein hormones, highlighting a growing trend toward reducing production costs and avoiding the use of serum or animal‐derived cell lines. However, optimization of the expression system to enhance molecular stability and in vivo half‐life and dose–response studies in ruminants are necessary. Although a few molecular modification strategies have yielded promising results in terms of stability, half‐life, and biological performance, to date, the only commercially available bovine recombinant FSH for use in livestock in South America is a ready‐to‐use long‐acting injectable formulation containing LA‐rbFSH (Zimbria, Ceva Saúde Animal). LA‐rbFSH is indicated for use in pubertal and cyclic female cattle in superovulation (SOV) and embryo transfer (ET) protocols, administered as a single dose. This molecule combines prolonged half‐life properties with effective biological activity and is currently employed in reproductive management protocols. Studies Using Bovine Recombinant FSH in Ruminants Given the growing interest in recombinant FSH molecules, studies have compared their effectiveness with purified FSH sources. Gutierrez‐Reinoso et al. (2025) evaluated bscrFSH in new SOV protocols for lactating dairy cows, comparing four applications (every 24 h) with two applications (at 48 h intervals) of 240 μg total dose. Cows receiving four injections showed more ovarian structures on day 8 (14.4 ± 1.2 vs. 12.8 ± 0.9), more transferable embryos (6.0 ± 0.5 vs. 5.2 ± 0.2), and fewer unfertilized oocytes (0.1 ± 0.0 vs. 0.3 ± 0.1). Despite these differences, circulating concentrations of 17β‐estradiol, FSH, LH, and P4 were not affected by treatments. These results indicate that the four‐application bscrFSH protocol is effective while requiring less handling than conventional regimens involving six to eight injections of purified FSH, and that the two‐application protocol can also induce a satisfactory superovulatory response, further reducing costs and handlings. Based on the advances achieved with bscrFSH, new sustained‐release formulations are being developed to reduce the number of injections and simplify management during superovulation in ruminants. In a recent study conducted by our group, Frata et al. (2025) compared conventional pFSH (225–450 IU) administered in eight doses with a single application of LA‐rbFSH (125–200 μg) for superovulation in Bos taurus and crossbreed cows and heifers and found no differences in total structures or transferable embryos. However, LA‐rbFSH resulted in a higher proportion of unfertilized oocytes (4.5% vs. 0%), whereas pFSH resulted in more degenerated embryos (25% vs. 18.4%). Furthermore, it is important to highlight that repeating the LA‐rbFSH treatment in the same cows up to four times did not affect the superovulatory response or the number of embryos. Da Silva et al. (2025) reported that administering 100 μg LA‐rbFSH on day 4 of a synchronization protocol increased embryo production (5.0 vs. 2.8) and blastocyst rate (40.6% vs. 31.1%) compared with the control group in Gir cows ( Bos indicus ) undergoing oocyte retrieval for in vitro fertilization. Therefore, these results indicate that LA‐rbFSH is not only as effective as the conventional pFSH protocol but also reduces animal handling. When evaluating the effects of follicular synchronization with recombinant bovine somatotropin (rBST) or LA‐rbFSH on follicular distribution, germinal vesicle (GV) stages, and transzonal projection (TZP) density in Nelore heifers and cows undergoing oocyte retrieval by OPU, Perecin et al. (2025) observed that, in heifers, both the control and rBST protocols yielded more COCs from small follicles, whereas LA‐rbFSH increased the recovery of oocytes from large follicles and the proportion at the GV3 stage. In cows, rBST also promoted the retrieval of COCs from small follicles compared with the control and LA‐rbFSH groups; however, no significant differences were found in GV‐stage distribution or TZP density. These results demonstrate that recombinant hormones can be strategically selected to modulate GV‐stage enrichment and improve in vitro maturation protocols. These findings highlight the potential of recombinant gonadotropins, particularly bscrFSH and LA‐rbFSH as promising alternatives to porcine pituitary‐derived products. Additionally, they offer the advantage of being developed based on the bovine FSH sequence, in contrast to rhFSH and LA‐rhFSH (Viana et al. 2024; Khodadadi et al. 2022). Although some limitations are still observed, including the need for optimization of dose and administration protocols and limited availability of large‐scale field studies, recombinant FSH has shown comparable or even superior biological performance across different production contexts (Table 1), while offering notable advantages such as the feasibility of single‐dose administration and, consequently, fewer handling procedures, thereby minimizing animal stress. Moreover, advances in cellular biotechnology, especially using CHO cell lines, have enabled the large‐scale production of these molecules with improved standardization and potential cost reductions in the medium and long term. Therefore, the use of rFSH is a promising tool for developing more efficient, standardized, and sustainable assisted reproduction protocols, particularly in response to the growing demand for safe and reproducible reproductive biotechnologies with minimal impact on animal management. TABLE 1Main ovarian and embryo production outcomes of studies evaluating recombinant follicle‐stimulating hormone (rFSH) in ruminants submitted to superovulation protocols.ReferencesMoleculeSpecies and categoryDoseMain resultsGutierrez‐Reinoso et al. (2025)bscrFSHLactating dairy cows ( Bos taurus )Four or two applications of 240 μgGreater number of total structures (14.4 ± 1.2 vs. 12.8 ± 0.9) and transferable embryos (6.0 ± 0.5 vs. 5.2 ± 0.2) for 4 vs. 2 applications, respectivelyFrata et al. (2025)LA‐rbFSH e pFSH Bos taurus and crossbreed cows and heifersHeifers: 125–150 μg LA‐rbFSH or 225–300 IU pFSH. Cows: 160–200 μg LA‐rbFSH or 300–450 IU pFSHTotal structures and transferable embryos did not differ between pFSH (8 doses) and LA‐rbFSH (single dose) treatmentsDa Silva et al. (2025)LA‐rbFSHGir ( Bos indicus ) cowsControl or 100 μg LA‐rbFSHIncreased in vitro embryo production (5.0 vs. 2.8) and a higher blastocyst rate (40.6% vs. 31.1%) for LA‐rbFSH compared with the control groupPerecin et al. (2025)LA‐rbFSH e rBSTNelore ( Bos indicus ) heifers and cowsControl, 100 μg LA‐rbFSH or 325 mg rBSTLA‐rbFSH increased the recovery of large‐follicles COCs and GV3 oocytes, and no differences were observed in GV stages or TZP density among treatmentsAbbreviations: μg: microgram; bscrFSH: recombinant bovine single‐chain follicle‐stimulating hormone (bovine ripafolitropin alfa); GV: germinal vesicle; IU: international units; LA‐rbFSH: recombinant bovine long‐acting follicle‐stimulating hormone (bovine ripafolitropin alfa); pFSH: purified follicle‐stimulating hormone; rBST: recombinant bovine somatotropin; TZP: transzonal projections. Main ovarian and embryo production outcomes of studies evaluating recombinant follicle‐stimulating hormone (rFSH) in ruminants submitted to superovulation protocols. Abbreviations: μg: microgram; bscrFSH: recombinant bovine single‐chain follicle‐stimulating hormone (bovine ripafolitropin alfa); GV: germinal vesicle; IU: international units; LA‐rbFSH: recombinant bovine long‐acting follicle‐stimulating hormone (bovine ripafolitropin alfa); pFSH: purified follicle‐stimulating hormone; rBST: recombinant bovine somatotropin; TZP: transzonal projections. Recent Advances in Recombinant eCG Development The eCG is a glycoproteic hormone produced by chorionic cells of pregnant mares, and it was first identified in 1930 as a factor present in the blood during the first third of gestation (Cole and Hart 1930). It is secreted by endometrial cups between days 37 and 120 of pregnancy in equine species and, like other chorionic gonadotropins, contains α and β subunits, with a high carbohydrate content, primarily composed of sialic acid residues that confers an extended half‐life (Flores‐Flores et al. 2014). In mares, eCG binds mainly to LH receptors (Stewart and Allen 1981), inducing accessory CLs during pregnancy; however, due to its unique structure, eCG can bind to both FSH and LH receptors in non‐equid species (reviewed by Murphy 2012). In cattle, the administration of eCG has been associated with beneficial effects on both follicular and luteal development, particularly in females in anestrus and with low body condition scores (BCS) (Baruselli et al. 2004). Depending on the dose and moment of administration, eCG treatment in cows reduces follicular atresia, increases recruitment and growth of small to large follicles, improves dominant and preovulatory follicle development, resulting in better CL quality, greater progesterone secretion, and higher pregnancy rates (De Rensis and López‐Gatius 2014). Despite its benefits, the commercial use of eCG has several limitations. Currently, the available formulations are extracted and purified from the blood of pregnant mares in early gestation, a process associated with major drawbacks, including animal welfare concerns due to repeated blood collections and, sometimes, pregnancy interruption, as well as marked batch‐to‐batch variability (Villarraza et al. 2021; Vilanova et al. 2019). Lösle et al. (2025) reported only 5.5% of similarity in protein composition when comparing four commercially available purified eCG products, highlighting substantial discrepancies among products on the market. Given the well‐documented benefits of eCG and the limitations of its purified form, recombinant eCG (reCG) has become a promising alternative, offering controlled production, elimination of animal use, and greater batch consistency. Villarraza et al. (2021) produced reCG in CHO‐K1 cells—a variant of CHO cells—using lentiviral vector systems as the gene delivery method, generating biologically active hormone. Subsequently, Byambaragchaa et al. (2025) also established a reCG system in CHO‐DG44 cells (derived from CHO‐K1) expressing a single‐chain form. The produced reCG activated FSH and LH receptors (eLH/CGR, rLH/CGR, rFSHR), stimulating cAMP production, pERK1/2 signalling, and β‐arrestin 2 recruitment in a dose and time‐dependent manner. These findings confirmed the biological functionality of reCG, capable of activating multiple intracellular pathways, and highlighted its potential as a promising alternative to replace animals as the source of eCG. In addition to eliminating the dependence on pregnant mares, recombinant production offers greater control over molecular structure, potential for industrial scaling, and long‐term cost reduction. Additional advantages include reduced labour demands by providing a ready‐to‐use formulation, reducing the risk of product loss or dosing errors. Improved standardization of biological responses further offers economic benefits through greater predictability and reduced losses from ineffective treatments. Thus, reCG represents not only a biotechnological innovation but also a sustainable and ethically preferable alternative for livestock reproductive management. Similar to rFSH, a single commercial product is currently available in Brazil (Foli‐Rec, Ceva Saúde Animal), with availability extending to other countries, supplied as a ready‐to‐use injectable solution for follicular growth induction in bovine TAI protocols. Studies Using reCG in Ruminants With advances in gene expression and cell culture technologies, several strategies have been developed to produce a functional reCG with biological activity comparable to the native molecule. Dose–response and field studies have been conducted in different animal models (Table 2). Villarraza et al. (2021) evaluated reCG in cows and heifers under field conditions, comparing its performance with purified eCG, and the results varied according to dose and protocol. In anestrous cows, the 140 IU dose achieved the best outcomes, with pregnancy rates of 45%, not differing from eCG (42.9%). In anestrous lactating crossbred beef cows, 140 IU of reCG and 400 IU of eCG produced similar dominant follicle diameters, and both increased ovulation rates relative to controls; however, ovulation occurred earlier with reCG. In another trial with Angus cows (up to 90 days postpartum), the same pregnancy rate (58%) was obtained with 140 IU of reCG or 400 IU of eCG, both significantly higher than other treatments and the control group. Collectively, these findings demonstrate that reCG has the potential to replace eCG in TAI. TABLE 2Main reproductive outcomes of studies evaluating reCG in ruminants in different reproductive biotechnologies (FTAI, ovulation induction, embryo transfer and superovulation).ReferencesAnimalsMain resultsVillarraza et al. (2021)Crossbred cowsPregnancy rate was significantly lower with the use of 400 IU reCG compared to 400 IU eCG (12% vs. 58%)Anestrous cowsPregnancy rates after FTAI did not differ among 100 IU reCG (33%), 140 IU reCG (45%), 200 IU reCG (30%) and 400 IU eCG (42.9%)Holstein heifersAfter SOV, 2000 IU reCG increased the number of follicles ≥ 8 mm, CL number, and follicular perfusion compared with 1000 IU reCG. CL number did not differ between 2000 IU reCG and 2500 IU eCGAnestrous lactating crossbred cowsFollicular dynamics during FTAI protocol revealed: no difference for dominant follicles diameter; higher ovulation rate in eCG‐treated groups (140 IU reCG: 80%; 400 IU eCG: 71%) compared to control (41%); and earlier ovulation in reCG and control compared to eCG‐treated cowsSuckled Angus cowsHigher pregnancy rate in reCG‐treated (reCG: 54% for 105 IU; 57% for 120 IU; and 58% for 140 IU) and 400 IU eCG‐treated (58%) cows compared to untreated control (41%)Cattaneo et al. (2024)Suckled beef cowsHigher estrus rate and P/AI after FTAI in reCG‐treated cows (105 IU: 79.9% and 53.5%; 140 IU: 76.9% and 52.3%) compared to control group (69.9% and 44.4%). Higher P/AI after FTAI for reCG (84 IU: 38.6%; 105 IU: 37.1%; 140 IU: 36.2%) compared to untreated control (28.2%). No difference in P/AI between 84 IU reCG (54%) and 300 IU eCG (59%), and lower P/AI in cows treated with 105 IU reCG (41%)Carvalho et al. (2026)Dairy cowsBoth doses increased P/AI after FTAI (45.2% for 105 IU and 42% for 140 IU reCG) compared to control (34.1%).Rodríguez et al. (2024)Heifers, primiparous and multiparous Angus cowsIn a Co‐synch FTAI protocol: higher estrus expression after treatment with eCG‐like (400 IU) compared to untreated control in primiparous (68.9% vs. 45.0%) and multiparous (75.5% vs. 68.8%) cows. In heifers 300 IU eCG‐like increased conception rate (65.2%), compared to untreated control (48.3%). The same was observed for primiparous cows treated with 400 IU eCG‐like (48.3% vs. 35.1%); CL area increased in heifers and multiparous cows, and progesterone tended to be higher in heifers treated with eCG‐likeCamozzato et al. (2026)Anestrous ewesHigher follicular growth for 105 IU reCG and 400 IU eCG compared to untreated control. Ovulation rate was higher for reCG (88.9%) and eCG (100%) compared to control (0%). Serum P4 was lower for 105 IU reCG compared to 400 IU eCG; pregnancy and conception rates during seasonal transition were not affected by eCG treatmentsRodrigues et al. (2025)Crossbred cowsNo difference in the percentage of treated‐to‐transferred rate (eCG 300 IU: 93.0%; reCG 105 IU: 85.0% and reCG140 IU: 84.4%) and in P/ET (eCG 300 IU: 42.3%; reCG 105 IU: 39.3%; and reCG140IU: 44.6%). Pregnancy loss was not affectedGretter et al. (2025)Nellore cowsAfter SOV, similar ovulation rate and embryo viability were observed among treatments with 100 μg LA‐bscrFSH, 100 μg LA‐bscrFSH + 175 IU reCG or 1.050 IU reCG; lower recovery rate with reCG alone; the rFSH + reCG combination did not improve embryo production, and reCG was as effective as rFSHBandeo et al. (2025)BuffaloesHigher‐quality oocytes obtained after treatment with 160 mg FSH and 2500 IU eCG. Embryo production was higher in buffaloes treated with FSH, but did not differ from 1050 IU reCG (1.5 vs. 1.05 embryos/buffalo/OPU). Higher cleavage rates in reCG‐treatedAbbreviations: eCG: equine chorionic gonadotropin; eCG‐like: eCG‐like glycoprotein; FTAI: fixed‐time artificial insemination; FTET: fixed‐time embryo transfer; IU: international units; LA‐bscrFSH: long‐acting bovine recombinant follicle‐stimulating hormone (bovine ripa‐follitropin alpha); P4: progesterone; reCG: recombinant equine chorionic gonadotropin. Main reproductive outcomes of studies evaluating reCG in ruminants in different reproductive biotechnologies (FTAI, ovulation induction, embryo transfer and superovulation). Abbreviations: eCG: equine chorionic gonadotropin; eCG‐like: eCG‐like glycoprotein; FTAI: fixed‐time artificial insemination; FTET: fixed‐time embryo transfer; IU: international units; LA‐bscrFSH: long‐acting bovine recombinant follicle‐stimulating hormone (bovine ripa‐follitropin alpha); P4: progesterone; reCG: recombinant equine chorionic gonadotropin. Continuing the evaluation of reCG under different production conditions, Cattaneo et al. (2024) assessed its effects on pregnancy rates in lactating beef cows synchronized with an estradiol/progesterone‐based TAI protocol. When comparing 140 and 105 IU, cows treated with reCG showed higher estrus expression and pregnancy per artificial insemination (P/AI) (105 IU: 79.9% and 53.5%; 140 IU: 76.9% and 52.3%) compared with control cows (69.9% and 44.4%). In subsequent trial testing 140, 105, and 84 IU, all reCG doses tended to increase P/AI relative to control (84 IU: 38.6%; 105 IU: 37.1%; 140 IU: 36.2%; control: 28.2%). Furthermore, reCG was compared with 300 IU of eCG. Cows receiving 84 IU of reCG achieved a P/AI (54%) similar to eCG (59%), both outperforming the 105 IU reCG group (41%). Overall, the authors concluded that reCG enhances fertility in suckling beef cows and that, although its efficacy is comparable to eCG, excessive reCG doses may reduce P/AI. Building upon this evidence, subsequent studies have further explored the influence of reCG dosage and protocol duration on fertility outcomes in cattle. In Holstein and crossbreed dairy cows, Carvalho et al. (2026) conducted two experiments evaluating the efficacy of reCG. In the first trial, greater pregnancy rates were obtained after TAI in Holstein cows treated with 400 IU eCG (36.8%) or 140 IU reCG (37.2%), compared to untreated cows (27.8%). In the second experiment, no significant difference was observed in pregnancy rates after TAI in Holstein and Holstein × Gir cows treated with 105 IU reCG (45.2%) or 140 IU reCG (42%), both treatments being superior to the control (untreated) group (34.1%). Together with previous results, these data reinforce the equivalence between eCG and reCG. Expanding this perspective, Rodríguez et al. (2024) demonstrated that the administration of an eCG‐like glycoprotein improves reproductive performance in cattle. In Angus cows synchronized with a 5‐day Co‐Synch protocol, the treatment increased ovulation and TAI pregnancy rates in primiparous (68.9% vs. 45.0%) and multiparous (75.5% vs. 68.8%) cows compared with controls. Conception rates also increased in heifers (65.2% vs. 48.3%), primiparous cows (48.3% vs. 35.1%), and multiparous cows with a BCS ≤ 4 (47.7% vs. 34.8%). Moreover, the eCG‐like treatment increased CL area in heifers and multiparous cows and tended to elevate serum progesterone concentrations in heifers. These results highlight the effectiveness of gonadotropin analogues in enhancing AI programs and the importance of considering category and BCS to optimize reproductive responses. In a recent study conducted by our group with seasonally anestrous ewes in Southern Brazil, Camozzato et al. (2026) demonstrated that ewes treated with eCG (400 IU) or reCG (105 IU) showed greater follicular growth than controls, with ovulation rates of 100% and 88.9%, respectively, while no ovulations occurred in controls. The CL area and blood perfusion were similar between eCG and reCG treated ewes, whereas serum progesterone concentrations were significantly higher in the eCG group. In a second experiment, estrus expression increased in eCG (95.27%) and reCG (88.97%) groups, compared to control (78.22%), but pregnancy (46.53% to 50%) and conception (51.45% to 56.78%) rates after natural mating did not differ among treatments. These findings indicate that reCG can achieve physiological responses comparable to eCG even during seasonal anestrus; however, further studies are required to evaluate their impact on fertility under deep anestrus conditions. In addition to TAI applications, recent studies highlight the effectiveness of reCG in SOV and ET. Rodrigues et al. (2025) reported similar ovulation and conception rates when comparing reCG (105 or 140 IU) with purified eCG (300 IU) in ET recipients (47%, 55.1% and 46.8%, respectively), with a tendency for higher responses in primiparous Nelore cows. Regarding in vivo embryo production, in Holstein heifers, 2000 IU of reCG increased the number of large follicles and CL during superovulation compared with 1000 IU reCG. However, there was no significant difference in the number of CL induced by 2000 IU reCG and 2500 IU eCG (Villarraza et al. 2021). Gretter et al. (2025) evaluated rFSH (100 μg rFSH), reCG (1050 UI reCG), and their combination (100 μg rFSH + 175 UI reCG) in SOV protocols for in vivo embryo production in Nelore donors and found similar ovulation rates (rFSH: 59%; rFSH + reCG: 56%; reCG: 56%) and numbers of large follicles and CLs across treatments. The number of viable embryos (rFSH: 4.3; rFSH + reCG: 4.1; reCG: 3.9) and embryonic viability were comparable among groups, indicating that reCG is effective in producing embryos comparable to those obtained with rFSH. The combination of rFSH and reCG did not improve embryo yield, reinforcing that individual use of either gonadotropin can achieve comparable embryonic outcomes. Overall, these findings indicate that reCG is a viable alternative to conventional eCG and FSH in ET and SOV programs, though broader evaluation is still required for its optimized application. Complementing the findings observed in cattle and sheep, Bandeo et al. (2025) compared pFSH, reCG, and eCG treatments before ovum pick‐up (OPU) in buffaloes and found no differences in the total numbers of follicles, oocytes, or zygotes. Higher‐quality oocytes were obtained with pFSH and eCG, while embryo yield was greater in buffaloes treated with pFSH but did not differ significantly from those treated with reCG (1.5 vs. 1.05 embryos/buffalo/OPU). Cleavage rates, however, were superior after reCG treatment. The overall evidence indicates that eCG and reCG play a fundamental role in the induction of follicular growth and ovulation, contributing to the success of reproductive programs. The consistent performance of reCG across different species and protocols highlights its biological efficiency and applicability. Continued research is essential to refine dosage and evaluate long‐term fertility outcomes. Conclusion Although the commercial use of recombinant hormones, such as rFSH and reCG, is still in the consolidation phase, studies have demonstrated several advantages. For rFSH, a single administration has proven to be as effective as conventional multi‐dose pFSH for superovulation, while reCG has shown comparable efficacy in promoting follicular growth and ovulation in ruminants. The potential to reduce interventions and handling procedures, decrease labour requirements, increase the predictability of hormonal responses, and eliminate dependence on animal‐derived products underscores their value as a biotechnological tool aligned with the demands for production efficiency, animal welfare and biosecurity. Although recombinant hormones still have a high initial cost and, at certain doses, may be more expensive than conventional purified hormones, their potential for cost reduction over time is noteworthy. As production scale increases, the cost per unit tends to decrease, making these products progressively more competitive. In addition, standardized production, greater hormone availability, and a high degree of purity may improve use efficiency, helping to reduce the cost per dose and expand their applicability. Further studies should be developed to validate the use of recombinant gonadotropins in other species, as well as to consolidate their use in cattle and sheep to refine indices and strategies. Author Contributions Vitória Leite Di Domenico, Fabiane Pereira de Moraes and Natália Ávila de Castro conducted the literature review and the initial draft of the manuscript; Fernando Caetano de Oliveira and Diogo Magnabosco provided overall supervision and co‐edited the manuscript; Fernando Caetano de Oliveira and Bernardo Garziera Gasperin edited and reviewed the final manuscript. Conflicts of Interest The authors declare no conflicts of interest.